Strikingly, in addition to the role of tenascin-C in ECM stiffness, it has also been reported to be highly expressed in RA patients and to modulate chronic inflammation in models of RA (46), reinforcing again the concept to target YAP during RA. The gene discussed is TNC; the disease is rheumatoid arthritis.